Sanofi bets on safer aspirin combos with $35M Pozen deal

Sanofi ($SNY) is handing over a $15 million upfront payment along with promises of $20 million in precommercialization milestones to partner with Chapel Hill, NC-based Pozen ($POZN) on a pair of new-and-improved aspirins that avoid some common side effects. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.